PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy / Reni, ; Cereda, ; Mazza, ; Passoni, ; Nicoletti, ; Balzano, ; Zerbi, ; Arcidiacono, P. G.; Staudacher, ; Di, Carlo; Reni, Michele. - In: AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS. - ISSN 0277-3732. - (2008). [10.1097/COC.0b013e31814688f7]
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy
Arcidiacono P.G.;RENI, MICHELE
2008-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
